Expert perspectives on the toxicity profile of immunotherapy agents and how they can be managed in patients being treated for advanced biliary tract cancers.
Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center
Advertisement
Articles by Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center
Centering their conversation on the TOPAZ-1 clinical trial, expert panelists review the use of IO + chemotherapy in advanced biliary tract cancers.
Centering discussion on early-stage biliary tract cancers, expert panelists consider the respective roles of surgery and embolization strategies in this setting.
Panelists share their perspectives on molecular testing guidelines for patients diagnosed with biliary tract cancers.
Comprehensive insight on staging biliary tract cancers followed by an overview of molecular testing and targetable clinicopathologic features.
Expert perspectives on the presentation of biliary tract cancers with specific insight to the challenges inherent in reaching a timely diagnosis.
Shared insight on the global incidence of biliary tract cancers and which risk factors most impact the likelihood of disease.
Opening their discussion on biliary tract cancers, a multidisciplinary panel of experts consider how specific subsets of these malignancies differ from one another.
Optimizing Precision Medicine in HCC
ByTanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Edward Kim, MD, Mount Sinai Medical Center,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Amit Singal, MD, UT Southwestern Medical Center,Rachna Shroff, MD, University of Arizona,Arndt Vogel, MD, Hannover Medical School,Mark Yarchoan, MD
Takeaways from a discussion on treatment advances in hepatocellular carcinoma.
Biomarkers to Guide HCC Treatment Decisions
ByTanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Edward Kim, MD, Mount Sinai Medical Center,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Amit Singal, MD, UT Southwestern Medical Center,Rachna Shroff, MD, University of Arizona,Arndt Vogel, MD, Hannover Medical School,Mark Yarchoan, MD
Professionals who treat patients with hepatocellular carcinoma comment on the need for more research and biomarkers to fuel treatment decisions.
Second-Line Treatment Approaches for Advanced HCC
ByTanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Edward Kim, MD, Mount Sinai Medical Center,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Amit Singal, MD, UT Southwestern Medical Center,Rachna Shroff, MD, University of Arizona,Arndt Vogel, MD, Hannover Medical School,Mark Yarchoan, MD
An overview of the second-line treatment landscape for patients with advanced hepatocellular carcinoma and considerations regarding the sequencing of novel therapies.
The COSMIC-312 Study in Advanced HCC
ByTanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Edward Kim, MD, Mount Sinai Medical Center,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Amit Singal, MD, UT Southwestern Medical Center,Rachna Shroff, MD, University of Arizona,Arndt Vogel, MD, Hannover Medical School,Mark Yarchoan, MD
Thoughts regarding the COSMIC-312 study of cabozantinib plus atezolizumab as frontline therapy for advanced hepatocellular carcinoma.
HCC: IO in Liver Transplant Recipients
ByTanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Edward Kim, MD, Mount Sinai Medical Center,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Amit Singal, MD, UT Southwestern Medical Center,Rachna Shroff, MD, University of Arizona,Arndt Vogel, MD, Hannover Medical School,Mark Yarchoan, MD
A debate regarding the appropriateness of immunotherapy following liver transplantation in patients with hepatocellular carcinoma.
The LEGACY Study in HCC
ByTanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Edward Kim, MD, Mount Sinai Medical Center,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Amit Singal, MD, UT Southwestern Medical Center,Rachna Shroff, MD, University of Arizona,Arndt Vogel, MD, Hannover Medical School,Mark Yarchoan, MD
Implications on treatment practices of the LEGACY study of Y-90 glass microspheres in patients with unresectable solitary hepatocellular carcinoma.
Selecting First-Line Therapy for Advanced HCC
ByTanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Edward Kim, MD, Mount Sinai Medical Center,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Amit Singal, MD, UT Southwestern Medical Center,Rachna Shroff, MD, University of Arizona,Arndt Vogel, MD, Hannover Medical School,Mark Yarchoan, MD
An overview of factors that deem patients appropriate for atezolizumab/bevacizumab vs lenvatinib or sorafenib as frontline therapy for advanced hepatocellular carcinoma.
Frontline IO for Advanced HCC
ByTanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Edward Kim, MD, Mount Sinai Medical Center,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Amit Singal, MD, UT Southwestern Medical Center,Rachna Shroff, MD, University of Arizona,Arndt Vogel, MD, Hannover Medical School,Mark Yarchoan, MD
Considerations regarding the use of nivolumab as frontline treatment for advanced hepatocellular carcinoma.
Systemic Treatment Advances for Advanced HCC
ByTanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Edward Kim, MD, Mount Sinai Medical Center,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Amit Singal, MD, UT Southwestern Medical Center,Rachna Shroff, MD, University of Arizona,Arndt Vogel, MD, Hannover Medical School,Mark Yarchoan, MD
Exciting developments using novel therapies as systemic treatment for advanced hepatocellular carcinoma.
Scoring/Classifying Patients With Advanced HCC
ByTanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Edward Kim, MD, Mount Sinai Medical Center,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Amit Singal, MD, UT Southwestern Medical Center,Rachna Shroff, MD, University of Arizona,Arndt Vogel, MD, Hannover Medical School,Mark Yarchoan, MD
Best practices using available scoring systems to evaluate and treat patients with advanced hepatocellular carcinoma.
Adjuvant Treatment Advances in Operable HCC
ByTanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Edward Kim, MD, Mount Sinai Medical Center,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Amit Singal, MD, UT Southwestern Medical Center,Rachna Shroff, MD, University of Arizona,Arndt Vogel, MD, Hannover Medical School,Mark Yarchoan, MD
Perspectives regarding treatment advances using adjuvant approaches that include immunotherapy to treat early-stage hepatocellular carcinoma.
Hepatic Arterial Infusion Chemotherapy for HCC
ByTanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Edward Kim, MD, Mount Sinai Medical Center,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Amit Singal, MD, UT Southwestern Medical Center,Rachna Shroff, MD, University of Arizona,Arndt Vogel, MD, Hannover Medical School,Mark Yarchoan, MD
Reactions to recent clinical abstracts that support the use of hepatic arterial infusions for chemotherapy delivery in hepatocellular carcinoma.
Neoadjuvant Therapy to Downstage HCC
ByTanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Edward Kim, MD, Mount Sinai Medical Center,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Amit Singal, MD, UT Southwestern Medical Center,Rachna Shroff, MD, University of Arizona,Arndt Vogel, MD, Hannover Medical School,Mark Yarchoan, MD
Reactions to treatment gaps in the neoadjuvant space for hepatocellular carcinoma and implications for incorporating data supporting newer, novel systemic therapies for appropriate patients.
Advances in Locoregional Therapy for Early Stage HCC
ByTanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Edward Kim, MD, Mount Sinai Medical Center,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Amit Singal, MD, UT Southwestern Medical Center,Rachna Shroff, MD, University of Arizona,Arndt Vogel, MD, Hannover Medical School,Mark Yarchoan, MD
University of Arizona’s Rachna Shroff, MD, describes the role of systemic therapy with locoregional treatment for early stage hepatocellular carcinoma and highlights treatment strategies of interest that remain under investigation.
Current Role of Locoregional Therapy for Early Stage HCC
ByTanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Edward Kim, MD, Mount Sinai Medical Center,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Amit Singal, MD, UT Southwestern Medical Center,Rachna Shroff, MD, University of Arizona,Arndt Vogel, MD, Hannover Medical School,Mark Yarchoan, MD
Edward Kim, MD, of Mount Sinai Health System describes where advances in locoregional therapy for early-stage hepatocellular carcinoma fit into the therapeutic landscape.
Diagnosing Early-Stage HCC via Biopsy
ByTanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Edward Kim, MD, Mount Sinai Medical Center,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Amit Singal, MD, UT Southwestern Medical Center,Rachna Shroff, MD, University of Arizona,Arndt Vogel, MD, Hannover Medical School,Mark Yarchoan, MD
A debate regarding the current role of biopsy to confirm a diagnosis of early-stage hepatocellular carcinoma.
Diagnostic Testing for Early Stage HCC
ByTanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Edward Kim, MD, Mount Sinai Medical Center,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Amit Singal, MD, UT Southwestern Medical Center,Rachna Shroff, MD, University of Arizona,Arndt Vogel, MD, Hannover Medical School,Mark Yarchoan, MD
The rationale for diagnostic imaging to evaluate and diagnose early stage hepatocellular carcinoma.
Screening for Early Stage HCC
ByTanios S. Bekaii-Saab, MD, FACP, Mayo Clinic,Edward Kim, MD, Mount Sinai Medical Center,Anjana Pillai, MD, University of Chicago Medicine Comprehensive Cancer Center,Amit Singal, MD, UT Southwestern Medical Center,Rachna Shroff, MD, University of Arizona,Arndt Vogel, MD, Hannover Medical School,Mark Yarchoan, MD
A brief overview of criteria and tools used to assess, and risk stratify patients with early stage hepatocellular carcinoma.
Advertisement
Latest Updated Articles
The LEGACY Study in HCCPublished: September 17th 2021 | Updated:
Neoadjuvant Therapy to Downstage HCCPublished: August 20th 2021 | Updated:
TOPAZ-1: Durvalumab + Doublet Chemotherapy in Advanced Biliary Tract CancersPublished: October 26th 2022 | Updated:
Current Role of Locoregional Therapy for Early Stage HCCPublished: August 13th 2021 | Updated:
Diagnosing Early-Stage HCC via BiopsyPublished: August 13th 2021 | Updated:
- Guidelines for Molecular Testing in Biliary Tract Cancers
Published: October 5th 2022 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
4
Nuvisertib Yields Strong Safety, Promising Efficacy in R/R Myelofibrosis
5